Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
Jun Zhang, MD, PhD
Study ID
NCT04680377
Status
Recruiting
Apply to this trial

Conditions

  • Locally Advanced Lung Carcinoma
  • NSCLC, Stage III

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.

Key Dates

Start date
Apr 12, 2021
Status verified
May 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
44 participants (estimated)

Arms

  • Arm: Participants receiving standard of care durvalumab
    Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment

Primary Outcome Measure

Grade 3 or higher adverse events (AE's) [ Time Frame: Up to 18 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The University of Kansas Cancer Center, Westwood CampusKansas CityKansas66205
Clinical Trials Nurse Navigator
[email protected]
913-945-7552
Rhode Island Hospital, Brown UniversityProvidenceRhode Island02905
Hina Khan, MD
[email protected]

Find similar trials in Kansas City, KS

By research site
The University of Kansas Cancer Center, Westwood Campus· Kansas City, KSRhode Island Hospital, Brown University· Providence, RI

Related Studies